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Abstract 
Psoriasis is a chronic inflammatory disease with a complex genetic architecture. To date, the 
psoriasis heritability is only partially explained. However, there is increasing evidence that the 
missing heritability in psoriasis could be explained by multiple genetic variants of low effect 
size from common genetic pathways. The objective of the present study was to identify new 
genetic variation associated with psoriasis risk at the pathway level. We genotyped 598,258 
SNPs in a discovery cohort of 2,281 case-control individuals from Spain. We performed a 
genome-wide pathway analysis using 1,053 reference biological pathways. A total of 14 
genetic pathways (PFDR≤2.55e-2) were found to be significantly associated with psoriasis risk. 
Using an independent validation cohort of 7,353 individuals from the UK, a total of 6 genetic 
pathways were significantly replicated (PFDR≤3.46e-2). We found genetic pathways that had 
not been previously associated with psoriasis risk like retinol metabolism (Pcombined=1.84e-4), 
the transport of inorganic ions and amino acids (Pcombined=1.57e-7) and post-translational 
protein modification (Pcombined=1.57e-7). In the latter pathway, MGAT5 showed a strong 
network centrality, and its association with psoriasis risk was further validated in an 
additional case-control cohort of 3,429 individuals (P<0.05). These findings provide insights 
into the biological mechanisms associated with psoriasis susceptibility. 
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Introduction 
Psoriasis  is a common chronic inflammatory disease of the skin that affects approximately 
2% of the worldwide population (Nestle et al., 2009). In psoriasis, immune cells infiltrate the 
skin leading to an increased proliferation of keratinocytes (Ferenczi et al., 2000; Gudjonsson 
and Elder, 2007). It is a genetically complex disease with a complex mode of inheritance 
(Vyse and Todd, 1996). HLA class I gene HLA-C*0602 haplotype association explains the 
largest part of the known heritability of psoriasis (Nair et al., 2006; Strange et al., 2010). 
Genome-wide association studies (GWAS) have been successful in the characterization of the 
genetic architecture of many complex human diseases (Manolio, 2010). To date, more than 15 
GWAS have been performed using large psoriasis cohorts from Caucasian and Asian 
populations and have collectively identified more than 50 susceptibility loci for psoriasis 
(Bowes et al., 2015; Tsoi et al., 2015b; Yin et al., 2015; Zuo et al., 2015). Despite progress in 
characterizing psoriasis genetic etiology, loci outside the HLA region only explain <25% of 
the estimated psoriasis heritability (Tsoi et al., 2012; Yin et al., 2014). 
Recent research has shown that the missing heritability of complex human diseases can be 
explained by common genetic variants, rare variants or a combination of genetic, epigenetic 
and environmental interactions (Gibson, 2012). From these, common genetic variants could 
explain >60% of the heritability of the most prevalent autoimmune diseases (Golan et al., 
2014). Importantly, most of these common genetic variants are characterized by having low 
effect sizes (Park et al., 2010). 
Although GWAS based on single markers have successfully identified disease-susceptibility 
variants, this strategy is not adequate to identify genetic variants with low effect sizes that are 
genuinely associated with disease risk (Du et al., 2012). In single-marker GWAS, a large 
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number of genetic variants are tested for association with a complex trait. In order to avoid 
false positive results, a stringent genome-wide significant threshold must be used (Johnson et 
al., 2010). This conservative threshold, however, does not allow the identification of modest 
effect risk loci, unless extremely large samples sizes of cases and controls are used (Wang et 
al., 2010). Importantly, single-marker GWAS consider only the individual effect of each SNP 
and ignore the joint effect of multiple causal genetic variants as well as the biological context 
where disease genes operate (Zhang et al., 2010). 
Functionally related genes have been shown to collectively contribute to disease 
susceptibility, including those loci that do not reach individually the genome-wide significant 
threshold (Zhong et al., 2010). Recently, new methods that are able to analyze genetic 
associations at the pathway level have been developed (Gui et al., 2011). Pathway-based 
approaches are robust statistical methodologies that integrate genetic and biological 
knowledge in order to test whether sets of functionally related genes are jointly associated 
with a complex trait (Ramanan et al., 2012). Therefore, pathway-based methods increase the 
statistical power of the association analysis by reducing the number of association tests that 
must be performed and allow a functional interpretation of the results (Wu et al., 2010). 
Pathway-based analyses have been recently performed to study the genetic basis of cancer 
subtypes using either selected candidate pathways, but also at a genome-wide scale (Chen et 
al., 2014; Koster et al., 2014). Although the genome-wide pathway analysis can have a high 
computational cost, this approach is able to identify novel genetic pathways associated with 
disease risk. The identification of new pathways associated with disease risk could increase 
the probability to develop new therapeutic strategies in complex diseases like psoriasis. To 
date, however, the genome-wide pathway analysis approach has not been performed in 
psoriasis. 
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To gain a better understanding of the genetic risk basis of psoriasis, we have performed a 
genome-wide pathway analysis on a large multicenter cohort of psoriasis patients. In the 
present study we have analyzed the association of 1,053 reference biological pathways using 
1,263 psoriasis patients and 1,558 controls from Spain. Using an independent cohort of 2,178 
cases and 5,175 controls from UK, we have then performed a validation study of the 
significantly associated pathways in the discovery cohort. With this approach, we have 
identified genetic pathways that had not been previously associated with psoriasis risk like 
retinol metabolism, transport of inorganic ions and amino acids and post-translation protein 
modification. These results provide important insights into the genetic etiology of psoriasis. 
 
Results 
Identification of genetic pathways associated with psoriasis risk 
In the discovery stage, the genome-wide pathway analysis identified a total of 26 genetic 
pathways significantly associated with psoriasis risk after multiple test correction (PFDR<0.05, 
Table S1). The complete results of the genome-wide pathway analysis performed in the 
discovery study are shown in Table S2. 
From the 26 significantly associated pathways, we found that 14 pathways included IL12B 
gene. After HLA-C*0602, IL12B is one of the strongest known genetic risk factors for 
psoriasis. In order to confirm that the observed pathway associations were the result of the 
joint effect of multiple genes and not the result of a single risk locus strongly associated with 
the disease, we removed IL12B from these genetic pathways and tested again for association. 
After extracting IL12B, two genetic pathways -“Inflammatory response” and “Natural killer T 
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cell”- remained significantly associated with psoriasis risk (PFDR<0.05). Consequently, only 
these two pathways from the group containing IL12B gene were selected for replication. 
Together with the other 12 pathways, a total of 14 different genetic pathways were finally 
tested for validation in the UK population. Using this independent case-control cohort we 
significantly validated the association of 9 genetic pathways with psoriasis risk (PFDR<0.05, 
Table 1). 
Characterization of the genetic pathways associated with psoriasis risk 
In order to discard the presence of redundant pathways, we evaluated the level of gene 
overlap between all associated pathways. From the 9 validated genetic pathways, we found 
that the “Amino acid transport across the plasma membrane” and “Transport of inorganic ions 
and amino acids” pathways, as well as the “Asparagine N-linked glycosylation”, “Transport 
to the Golgi and subsequent modification” and “Post-translational protein modification” 
pathways had a high degree of overlap between them (>95% of shared genes, Figure 1a). 
Consequently, and in order to avoid redundancy, only the pathway showing the highest level 
of significance was selected to represent each biological process. The “Transport of inorganic 
ions and amino acids” (Pcombined=1.57e-7, Figure 1b) and “Post-translational protein 
modification” (Pcombined=1.57e-7, Figure 1c) pathways were therefore selected from each 
overlapping pathway group. The “Inflammatory response” (Pcombined=1.06e-12), “Natural 
killer T cell” (Pcombined=1.06e-12), “DNA repair” (Pcombined=1.10e-9) and “Retinol 
metabolism” (Pcombined=1.84e-4) pathways did not show a significant degree of overlap and 
were therefore considered as independent biological processes. 
Within the final group of 6 genetic pathways associated with disease risk and representing 
independent biological processes, we analyzed the association between each particular gene 
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and psoriasis risk (Table 2). We found 37 small-effect genes that were nominally associated 
with psoriasis risk both in the discovery and replication cohorts (P≤1.29e-2, Table 3). The 
complete list of genetic associations obtained from each genetic pathway is shown in Table 
S3. The linkage disequilibrium pattern between the SNPs mapping to each genetic pathway 
associated with psoriasis risk is shown in Figure S1. 
Functional-based networks associated with psoriasis risk 
In order to understand the relevance of each particular gene within the genetic pathway 
associated with psoriasis risk, we used biological knowledge to build the associated 
functional-based network (Figure 2). Using known or predicted functional associations 
between the pathway genes, functional-based networks are a powerful approach to represent 
and analyze the topological structure of a biologic pathway.  
In order to characterize the network properties of the resulting functional-based networks, we 
determined the betweenness centrality (BC) and degree centrality (DC) statistics (Table S4). 
These two measures are useful to identify those network elements (genes in this case) that are 
likely to be more influential in the structure of the network. BC and DC have been widely 
used to identify the genes that are more likely to be essential for pathway functionality (Hahn 
and Kern, 2005; Joy et al., 2005; Vallabhajosyula et al., 2009). We found that SLC7A11 from 
the “Transport of inorganic ions and amino acids” pathway and MGAT5 from the “Post-
translational protein modification” pathway had markedly high BC values (BC≥0.1). From 
these, MGAT5 gene showed also a much stronger DC value than SLC7A11 (DCMGAT5=19, 
DCSLC7A11=3). 
Given the strong network centrality properties found for MGAT5 gene in the “Post-
translational protein modification” pathway, we decided to further test the association of this 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
9 
 
key gene with psoriasis risk in an independent case-control cohort. Using this additional 
replication cohort, we significantly validated the association of MGAT5 gene with psoriasis 
risk (P=1.3e-2, OR (95% CI)=0.85 (0.74-0.96)). 
Functional analysis of MGAT5 variation 
MGAT5 encodes for a key enzyme in the N-glycosylation pathway, a post-translational 
process that is directly implicated in T cell activation and differentiation (Demetriou et al., 
2001). In order to assess the functional role of MGAT5 in psoriasis pathogenesis, we 
evaluated the association between genetic variation at MGAT5 gene and the levels of T cell 
surface glycosylation. Flow cytometry analysis of in vitro activated CD4+ and CD8+ T cells 
obtained from 27 psoriasis patients showed an increase in N-glycosylation levels in patients 
carrying 1 or 2 copies of the protective allele (G) compared to homozygous individuals for the 
risk allele (A) (Figure 3). The increased glycosylation levels in individuals carrying at least 
one copy of (G) allele was observed both in activated CD8+ and CD4+ T cells. In CD4+ T 
lymphocytes, the glycosylation level was significantly higher in GG homozygotes compared 
to AA homozygotes (P=0.01, Figure 3). 
 
Discussion 
Genome-wide association analyses have successfully identified more than 50 loci associated 
with psoriasis susceptibility. To date, however, the genetic basis of psoriasis is still not 
completely understood. In the present study we have performed a genome-wide pathway 
analysis of psoriasis genetic risk. Using a discovery cohort from Spain and an independent 
cohort from UK, we have identified and validated the association of 6 genetic pathways with 
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psoriasis susceptibility. Importantly, these validated pathways include biological processes 
like retinol metabolism, transport of inorganic ions and amino acids and post-translational 
protein modification that had not been previously associated with psoriasis risk at the genetic 
level. Additionally, analyzing the network properties of these validated pathways we have 
found that MGAT5 gene has a strong centrality in the post-translational protein modification 
pathway. Using an additional independent case-control cohort from Spain, we have further 
replicated the association of MGAT5 with psoriasis risk. Taken together, these findings 
contribute to a better understanding of the genetic risk basis of psoriasis and provide 
important insights into the biological mechanisms associated with the disease pathogenesis. 
Retinol  has been demonstrated to inhibit inflammatory processes in dermatological diseases 
(Balato et al., 2013). In particular, retinol inhibits the regulatory activity of the nuclear factor 
kappa B (NFKB) in the skin (Austenaa et al., 2004). NFKB is an established transcriptional 
factor that regulates multiple proinflammatory genes that are key in psoriasis pathogenesis 
like tumor necrosis factor and interleukin-17 (Goldminz et al., 2013). The NFKB signaling 
pathway has also been associated to the regulation of the proliferation of epidermal 
keratinocytes (Tsuruta, 2009). These findings are consistent with the elevated levels of NFKB 
that have been found in lesional and non-lesional psoriatic skin samples compared to non-
psoriatic skin (Lizzul et al., 2005). Therefore, genetic variation in the retinol metabolism 
pathway could reduce the retinol production leading to a weakened NFKB signaling and, 
consequently, promoting both inflammatory and proliferative hallmarks of psoriasis. 
Psoriasis risk was also associated with the genetic pathway implicated in the transport of both 
inorganic ions and amino acids. An increased transport of inorganic ions in CD4+ helper T 
cells has been shown to contribute to autoimmune and inflammatory diseases (Lang et al., 
2014). In particular, the intracellular transport of calcium is crucial for controlling the 
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expression of proinflammatory genes in immune cells (Khananshvili, 2013; Vig and Kinet, 
2009). Accordingly, the transport of inorganic ions and amino acids pathway associated with 
psoriasis risk includes the SLC8A1 gene, which modulates the cytoplasmic calcium 
concentration (Clapham, 2007). The transport of amino acids into T cells is essential to 
maintain the increased production of proinflammatory cytokines in activated human T cells 
(Hayashi et al., 2013). Importantly, the expression of amino acid transporters has been found 
to be differentially regulated in psoriatic inflammatory processes (Jaeger et al., 2008). These 
results therefore suggest that genetic variation in the transport of amino acids and inorganic 
ions pathway could increase the risk to develop psoriasis by modulating T cell functionality. 
The post-translational protein modification pathway is responsible for the N-linked 
glycosylation of the asparagine residues in the HLA molecules (Rudd et al., 2001). This post-
translational modification pathway has been found to be necessary for the immune system 
tolerance to self antigens (Ryan and Cobb, 2012). Previous studies have found that a deficient 
or aberrant asparagine glycosilation can induce autoimmune diseases (Green et al., 2007). 
Also, post-translationally modified autoantigens have been associated with psoriasis (Iversen 
et al., 2011). In psoriasis patients, the peptide glycosylation activity has been found to be 
markedly increased in comparison to healthy controls (Damasiewicz-Bodzek and 
Wielkoszynski, 2012). Furthermore, specific post-translational modifications on glycoproteins 
expressed on the surface of T lymphocytes have been shown to target these cells to the 
inflamed skin (Fuhlbrigge et al., 1997). Therefore, genetic variation in the post-translational 
protein modification pathway could perturb the glycosylation processes that are crucial to 
maintain the immune system tolerance. 
MGAT5 encodes for a key enzyme in the N-glycosylation pathway. This pathway has been 
directly implicated in T cell activation and autoimmunity (Demetriou et al., 2001). Recent 
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research has found an association between MGAT5 glycosylation activity and multiple 
sclerosis aetiology both in experimental models and in humans (Grigorian and Demetriou, 
2011; Mkhikian et al., 2011). In the present study, we have found that the MGAT5 is a key 
gene in the post-translational protein modification pathway associated with psoriasis. 
Subsequently, we found that genetic variation at MGAT5 is associated with the level of 
glycosylation of in vitro activated T cells. This result is consistent with previous findings 
showing that deficiency of MGAT5 glycosylation activity reduces the T-cell activation 
threshold and, consequently, promotes the triggering of autoimmune diseases (Demetriou et 
al., 2001). Further studies evaluating the implication of the T cell surface glycosylation in 
clinically relevant outcomes in psoriasis like skin severity are warranted. 
The association of psoriasis risk with the inflammatory response and the natural killer T cell 
pathways involves more than 10 immune-related genes, including IL12B. In a recent pathway 
analysis study using association results of a meta-analysis for psoriasis risk (Tsoi et al., 
2015a), these two pathways were also found to be associated. These findings, however, were 
not validated using an independent cohort. Our study, therefore, provides strong confirmation 
of the implication of these two genetic pathways in the risk of psoriasis. Also, the permutation 
based approach used in our study allowed to control for the potential bias associated with the 
presence of strong LD patterns within genes. Our results indicate that the association of these 
pathways is not only driven by IL12B gene, but it is the result of the joint contribution of other 
small-effect genes in these pathways. One of these genes is CXCR4, which encodes for a 
chemokine receptor from the natural killer T cell pathway (Colantonio et al., 2002). Although 
CXCR4 gene has not been previously associated with psoriasis risk in single-marker GWAS, 
CXCR4 chemokine has been shown to reduce keratinocyte proliferation and, consequently, 
the expansion of psoriatic plaques by regulating the proliferative cytokine signals that are 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
13 
 
activated in psoriatic lesions (Takekoshi et al., 2013). In addition, the inflammatory 
angiogenesis of psoriatic skin that leads to vascular remodeling has been recently shown to be 
modulated by CXCR4 chemokine (Zgraggen et al., 2014). Using the pathway analysis we can 
therefore identify small-effect genes like CXCR4 that cannot be detected by single-marker 
GWAS but that are biologically implicated in key processes of the disease pathophysiology. 
In the present study, we have also found a significant association between the DNA repair 
genetic pathway and psoriasis risk. Together with the dysregulation of immune system 
processes, the epidermal hyperproliferation is another well-known biological process 
implicated in the psoriasis pathophysiology (Wolf et al., 2012). The application of ultraviolet 
radiation in psoriasis skin lesions to induce apoptosis in aberrantly proliferating keratinocytes 
has proved to be a successful treatment for the clearance of plaque psoriasis in approximately 
70% of patients (Weatherhead et al., 2011). The ultraviolet radiation induces DNA damage 
that promotes the transcription of the DNA repair pathway genes (Roos and Kaina, 2006). 
Consequently, the enzymatic machinery of the pathway repairs the DNA damage and also 
triggers the cell death by activating the p53 apoptotic signaling (Lavin et al., 2005). 
Therefore, these results suggest that genetic variation in the DNA repair pathway promote an 
inefficient activation of the p53 apoptotic signaling that leads to an increased keratinocyte 
proliferation, as well as an inefficient response to ultraviolet therapy in psoriasis patients. 
Although the pathway-based analysis is a powerful approach to identify small-effect genetic 
variants associated with disease risk, this methodology is not exempt of limitations. Intergenic 
SNPs across the whole genome that map physically far away from genes were not included in 
the present study. These genetic variants could be known risk loci (e.g. rs12188300 is 
associated with psoriasis risk and is located at >20Kb from IL12B gene) or may regulate the 
expression of genes through cis- and trans-eQTL mechanisms (Gilad et al., 2008). Also, some 
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SNPs might not be functionally related to the closest genes. With the increasing regulatory 
information derived from eQTL and epigenomic data (Bernstein et al., 2010; Martens and 
Stunnenberg, 2013; Raney et al., 2011), intergenic SNPs could be integrated in the pathway-
based analysis in the next years. 
The complex linkage disequilibrium structure of the HLA region together with the strong 
association with the susceptibility to multiple common diseases, has been shown to generate 
false positive results in pathway-based methods (Wang et al., 2010). Following recent studies, 
in the present study we removed the SNPs mapping to this locus in order to perform the 
present pathway analysis (Chen et al., 2014). As a result, known pathways associated with 
psoriasis risk which include genes from the HLA region, like the NFKB pathway, were not 
analyzed in the present study. Importantly, however, in this study we have found and 
validated the association between genetic pathways related to IL12 signaling, an established 
genetic risk pathway for psoriasis and psoriasis risk. Also, within the associated pathways 
there are known risk genes for psoriasis (e.g. REV3L and IL4 within the DNA repair and 
inflammatory response pathways, respectively). Together, these results confirm the accuracy 
of the present pathway-based approach to identify relevant genetic variation associated with 
psoriasis risk. 
The present genome-wide pathway analysis has two important strengths. First, we used 
PLINK software to identify genetic pathways associated with psoriasis risk. This pathway 
analysis method uses genotype data in contrast to the methodologies that are only based on 
association statistics. An important limitation of these latter methodologies is that they do not 
account for the linkage disequilibrium between SNPs. This can result in highly biased results 
and a significant increase in false positive results (Wang et al., 2010). Instead, the pathway 
analysis approach that we used, although it can be computationally costly, it efficiently 
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overcomes these biases by maintaining the correct linkage disequilibrium patterns between 
SNPs. Finally, compared to previous pathway-based studies in other complex diseases, we 
have performed a two-stage pathway analysis in two large cohorts from different populations. 
Using an independent population, we have validated genetic pathways associated with 
psoriasis risk. 
In conclusion, using a genome-wide pathway analysis approach we have identified to our 
knowledge previously unreported genetic pathways associated with psoriasis risk. These 
biological pathways include retinol metabolism, transport of inorganic ions and amino acids 
and post-translational protein modification. The results of the present study represent an 
important contribution to the characterization of the genetic risk basis of psoriasis. 
 
Materials and methods 
Study population 
A total of 1,263 patients with psoriasis and 1,558 controls were recruited for the discovery 
stage. An independent case-control cohort of 7,353 individuals from UK was used to validate 
the significantly associated pathways in the discovery cohort. An independent cohort of 1,381 
psoriasis patients and 2,048 controls from Spain was used to replicate the association between 
MGAT5 gene and psoriasis risk (Supplemental Material) 
All the procedures were followed in compliance with the principles of the Declaration of 
Helsinki and all patients provided written informed consent to participate in this study. The 
study and the consent procedure were approved by the local Institutional Review Board of 
each participating center. 
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DNA extraction and genome-wide genotyping 
GWAS genotyping of the 2,821 individuals from the discovery cohort was performed using 
Illumina Quad610 Beadchips (Illumina, San Diego, California, USA) (Supplemental 
Material). After the quality control analysis, a final data set of 541,926 SNPs and 1,172 
psoriasis patients was available for the pathway-based analysis. The genome-wide genotyping 
of the psoriasis patients from the validation stage was performed using the Illumina 
Human660W-Quad (Illumina, San Diego, California, USA) and the healthy controls were 
genotyped using the Illumina custom Human1.2M-Duo (Illumina, San Diego, California, 
USA) as it has been previously described (Strange et al., 2010). The final data set used for the 
replication study included 515,703 SNPs from 2,178 psoriasis patients. The genotyping of the 
MGAT5 replication cohort was performed using the Taqman Real-Time PCR platform 
(Applied Biosystems) (Supplemental Material). 
Pathway-based analysis 
Gene set definition 
Reference biological pathway annotation databases BioCarta (www.biocarta.com), Kyoto 
Encyclopedia of Genes and Genomes (KEGG) (Kanehisa and Goto, 2000) and Reactome 
(Croft et al., 2014) were used to determine the global pathways (Supplemental Material). The 
final gene set included in the present study was composed by 215,948 SNPs mapping to 1,053 
pathways. 
Gene-set association analysis 
The statistical association analysis was performed using the PLINK set-based test (Purcell et 
al., 2007) (Supplemental Material). In order to obtain the global statistical significance of 
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each validated pathway, we combined the empirical P-values resulting from the discovery and 
replication stages using the Fisher’s method (Kugler et al., 2010). We tested the association of 
1,053 pathways with psoriasis risk. The False Discovery Rate (FDR) method (Hochberg and 
Benjamini, 1990) was used to account for multiple testing. 
Sensitivity analysis by removing the HLA and IL12B loci 
In pathway-based analysis, the presence of a single marker with very strong effects can lead 
to false positive associations. In these cases, the joint contribution of the pathway genes to 
disease risk is masked and not adequately evaluated (Wang et al., 2010). Similar to previous 
studies, in order to avoid this type of spurious associations, we removed all SNPs mapping to 
the HLA region (Megabases 25.6 to 33.3 in chromosome 6) (Chen et al., 2014). In the 
discovery stage, we found genetic pathways in which the IL12B gene was significantly 
associated with disease risk at a genome-wide scale. IL12B is a well-known psoriasis risk 
gene that shows a large effect on disease susceptibility and, like HLA region, could generate 
false positive results (Cargill et al., 2007; Nair et al., 2008; Zhu et al., 2013). Accordingly, we 
removed this psoriasis susceptibility locus (from 158,741,791 to 158,757,481 base pairs in 
chromosome 5) from the significant pathways and we repeated the analysis. We excluded 73 
and 58 SNPs from the discovery and replication studies, respectively. 
Characterization of the genetic pathways associated with psoriasis risk 
Genetic pathways involved in similar biological processes may share genes. In order to 
identify pathways representing different and independent biological processes, we computed 
the gene overlap between each pair of genetic pathways associated with psoriasis risk 
(Supplemental Material). 
The statistical significance of the association between pathway genes and psoriasis risk was 
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determined according to the most significant SNP mapping to each particular gene. 
 
Analysis of the functional-based networks associated with psoriasis risk 
The biological knowledge representing the functional association between gene pairs was 
used to build the functional-based network of each genetic pathway associated with psoriasis 
risk. In order to identify those genes that are more likely to play a central role in the genetic 
pathways associated with psoriasis risk, we analyzed the network statistical properties of each 
functional-based network (Suplementary Material). Using the genes that were nominally 
associated with psoriasis risk in both discovery and replication stages, we identified the most 
influential gene according to the highest values of these network statistics. 
Functional analysis of MGAT5 variation 
Following the methodology previously described (Chen et al., 2009), we evaluated the 
association of MGAT5 psoriasis risk variant with the level of cell surface glycosylation of in 
vitro activated CD4+ and CD8+ T cells isolated from n=27 psoriasis patients (Supplemental 
Material). 
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Tables 
PATHWAY DATABASE GENES SNPSD1 PD FDRD PDE FDRDE SNPSR1 PR FDRR PRE FDRRE PC 
Inflammatory response * Biocarta 29 628 <9.99e-8 5.25e-5 1.35e-2 4.71e-2 606 <3.33e-7 5.77e-7 1.53e-2 1.58e-2 1.06e-12 
Natural killer T cell * Biocarta 29 638 <9.99e-8 5.25e-5 1.17e-2 4.71e-2 603 <3.33e-7 5.77e-7 1.59e-2 1.59e-2 1.06e-12 
DNA repair * Reactome 112 2050 1.33e-4 9.36e-3 - - 1962 <3.33e-7 5.77e-7 - - 1.10e-9 
Amino acid transport across the plasma membrane Reactome 31 1025 2.00e-4 1.24e-2 - - 993 4.00e-5 5.63e-5 - - 1.57e-7 
Post-translational protein modification Reactome 188 5965 2.00e-4 1.24e-2 - - 5725 4.00e-5 5.63e-5 - - 1.57e-7 
Transport to the Golgi and subsequent modification Reactome 33 1557 3.33e-4 1.95e-2 - - 1516 3.20e-3 4.38e-3 - - 1.57e-5 
Asparagine N-linked glycosylation Reactome 81 2760 4.00e-4 2.11e-2 - - 2639 8.67e-3 1.13e-2 - - 4.72e-5 
Transport of inorganic ions and amino acids Reactome 94 4010 4.00e-4 2.11e-2 - - 3872 2.00e-5 3.25e-5 - - 1.57e-7 
Retinol metabolism KEGG 64 1512 5.33e-4 2.55e-2 - - 1406 2.79e-2 3.46e-2 - - 1.84e-4 
 
Table 1. Pathways associated with psoriasis risk and validated in the replication stage. 
Abbreviations: C, combined; D, discovery cohort; E, exclusion IL12B gene; FDR, False Discovery Rate; P, empirical set-based P-value; R, replication cohort. 
 
1 Number of Single-Nucleotide Polymorphisms mapping to a particular pathway. 
* Increased permutations to refine the P-value (n=10,000,000). 
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Table 2. Association results of the top five genes involved in each pathway associated with psoriasis risk. 
 
Abbreviations: A1, minor allele; A2, major allele; COORD, SNP coordinates in build GRCh37/hg19; D, discovery cohort; OR, odds ratio; P, P-value; R, 
replication cohort. 
 
1 The detailed description of the “Inflammatory response” and “Natural killer T cell” pathways corresponds to the association results after excluding the IL12B gene from the genome-wide 
pathway analysis. 
PATHWAY1 DATABASE SNPD
 
COORD A1 A2 ORD PD GENED SNPR COORD A1 A2 ORR PR GENER 
Inflammatory response Biocarta rs20541 5:131995964 A G 0.72 4.18e-5 IL13,IL4 rs2965012 1:218786549 A C 0.83 7.56e-4 TGFB2 
  
rs11739623 5:131864152 A G 1.21 1.79e-3 IL5 rs2243123 3:159709651 G A 1.14 1.06e-3 IL12A 
  
rs2799083 1:218581617 G A 1.22 2.82e-3 TGFB2 rs25890 5:131437562 G A 0.88 1.09e-3 CSF2 
  
rs2366408 3:159696099 A C 1.19 3.35e-3 IL12A rs20541 5:131995964 A G 0.86 2.41e-3 IL13,IL4 
  
rs2069837 7:22768027 G A 1.33 3.93e-3 IL6 rs4963517 12:6947800 A G 0.90 2.94e-3 CD4 
Natural killer T cell Biocarta rs20541 5:131995964 A G 0.72 4.18e-5 IL4 rs4297265 1:67852335 G A 0.83 4.01e-7 IL12RB2 
  
rs11739623 5:131864152 A G 1.21 1.79e-3 IL5 rs749873 2:136817088 G A 0.84 2.61e-5 CXCR4 
  
rs2799083 1:218581617 G A 1.22 2.82e-3 TGFB2 rs2965012 1:218786549 A C 0.83 7.56e-4 TGFB2 
  
rs2114808 2:137249556 G A 0.81 3.09e-3 CXCR4 rs2243123 3:159709651 G A 1.14 1.06e-3 IL12A 
  
rs2366408 3:159696099 A C 1.19 3.35e-3 IL12A rs25890 5:131437562 G A 0.88 1.09e-3 CSF2 
Retinol metabolism KEGG rs2173201 4:100250970 A C 0.77 5.82e-5 ADH1C,ADH1B rs7188923 16:81336356 A G 0.89 1.81e-3 BCMO1 
  
rs4148295 4:70475866 C A 1.23 3.41e-4 UGT2A1 rs10882144 10:94852448 A G 0.87 2.55e-3 CYP26A1 
  
rs17614939 4:70360229 G A 0.78 5.21e-4 UGT2B4 rs4319546 12:57346828 A G 0.89 4.96e-3 RDH16 
  
rs2279345 19:41515702 A G 0.84 2.44e-3 CYP2B6 rs4405788 2:72235688 A G 0.90 5.48e-3 CYP26B1 
  
rs17864686 2:234591339 A G 1.25 3.37e-3 UGT1A8 rs11670760 19:41336795 G A 1.12 5.73e-3 CYP2A6 
DNA repair Reactome rs240956 6:111616051 A C 1.46 3.16e-6 REV3L rs458017 6:111696091 G A 1.65 1.40e-13 REV3L 
  
rs20541 5:131995964 A G 0.72 4.18e-5 RAD50 rs2240116 9:35094373 A G 1.36 5.22e-4 FANCG 
  
rs2213178 8:48816716 A G 1.29 6.11e-5 PRKDC rs7099120 10:131015367 A G 1.15 9.51e-4 MGMT 
  
rs2985689 14:50098031 C A 1.28 1.66e-3 POLE2 rs3783819 14:61316264 A G 0.89 1.13e-3 MNAT1 
  
rs1887181 10:131594850 G A 1.46 1.86e-3 MGMT rs11693731 2:58887650 A G 0.89 1.13e-3 FANCL 
Post-translational protein modification Reactome rs1007108 1:26104973 A G 1.43 2.74e-6 MAN1C1 rs9886302 7:70751484 A G 0.81 7.29e-6 WBSCR17 
  
rs10865331 2:62551472 A G 1.25 7.88e-5 B3GNT2 rs7220464 17:7210836 A C 0.85 2.09e-5 EIF5A 
  
rs3791312 2:135183045 G A 0.71 8.04e-5 MGAT5 rs4528932 3:118941441 A G 1.17 5.28e-5 B4GALT4 
  
rs1495086 8:15378013 A G 0.78 1.02e-4 TUSC3 rs7780461 7:151641016 A G 1.24 8.26e-5 GALNTL5 
  
rs977905 3:5882683 G A 1.24 1.69e-4 EDEM1 rs12262718 10:17343706 A G 1.31 8.68e-5 ST8SIA6 
Transport of inorganic ions and amino acids Reactome rs12661704 6:111560890 A G 1.60 2.34e-7 SLC16A10 rs12661704 6:111560890 A G 1.42 2.38e-9 SLC16A10 
  
rs10205402 2:40710953 A G 0.77 8.78e-6 SLC8A1 rs2385844 2:220839453 G A 0.85 9.23e-6 SLC4A3 
  
rs532237 20:48467560 G C 1.31 1.09e-4 SLC9A8 rs6012750 20:48430680 A G 0.86 6.81e-5 SLC9A8 
  
rs538385 13:30229665 G A 0.82 6.91e-4 SLC7A1 rs1874361 1:205908186 A C 1.15 1.63e-4 SLC26A9 
  
rs17050441 4:139402774 G A 1.27 1.14e-3 SLC7A11 rs11668878 19:47268373 A C 1.27 1.65e-4 SLC1A5 
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Table 3. Genes associated with psoriasis risk in the discovery and replication stages for 
each validated pathway.  
Abbreviations: D, discovery cohort; OR, odds ratio; P, P-value; R, replication cohort. 
 
1
 The detailed description of the “Inflammatory response” and “Natural killer T cell” pathways corresponds to the association 
results before excluding the IL12B gene from the genome-wide pathway analysis. 
 
2 Genes contained in the genetic pathways that were nominally associated with psoriasis risk in the discovery and replication 
stages. 
PATHWAY1 DATABASE GENE2 PD PR 
Inflammatory response Biocarta IL12A 3.35e-3 1.06e-3 
  
IL12B 3.02e-10 1.69e-18 
  
IL13 4.18e-5 2.41e-3 
  
IL4 4.18e-5 2.41e-3 
  
TGFB2 2.82e-3 7.56e-4 
Natural killer T cell Biocarta CXCR4 3.09e-3 2.61e-5 
  
IL12A 3.35e-3 1.06e-3 
  
IL12B 3.02e-10 1.69e-18 
  
IL4 4.18e-5 2.41e-3 
  
IL4R 7.35e-3 1.37e-3 
  
TGFB2 2.82e-3 7.56e-4 
Retinol metabolism KEGG ADH1B 5.82e-5 1.21e-2 
  
UGT2B4 5.21e-4 6.13e-3 
  
RPE65 5.10e-3 7.34e-3 
DNA repair Reactome FANCL 3.22e-3 1.13e-3 
  
MGMT 1.86e-3 9.51e-4 
  
RAD50 4.18e-5 2.41e-3 
  
REV3L 3.16e-6 1.40e-13 
  
RFC3 2.14e-3 1.94e-3 
Transport of inorganic ions and amino acids Reactome SLC16A10 2.34e-7 2.38e-9 
  
SLC1A4 2.04e-3 7.44e-3 
  
SLC38A1 1.34e-3 9.44e-3 
  
SLC43A2 1.29e-2 1.15e-2 
  
SLC7A1 6.91e-4 6.62e-3 
  
SLC7A11 1.14e-3 6.22e-3 
  
SLC7A7 5.09e-3 2.77e-3 
  
SLC8A1 8.75e-6 1.30e-3 
  
SLC9A8 1.09e-4 6.81e-5 
  
SLC9A9 4.37e-3 3.22e-3 
Post-translational protein modification Reactome ALG10 3.89e-3 4.15e-3 
  
B3GNT2 7.88e-5 1.01e-3 
  
EDEM1 1.69e-4 5.81e-4 
  
EIF5A 3.42e-4 2.09e-5 
  
FUT8 5.30e-3 1.87e-4 
  
GALNT1 5.22e-4 9.72e-4 
  
MAN1A1 2.82e-4 1.04e-2 
  
MAN2A1 7.29e-3 3.53e-3 
  
MGAT5 8.04e-5 9.34e-3 
  
SEMA6D 2.06e-3 1.46e-3 
  
ST8SIA6 8.17e-3 8.68e-5 
  
TUSC3 1.02e-4 6.07e-3 
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Figure Legends 
 
Figure 1. Gene overlap of genetic pathways associated with psoriasis risk. A: Heat-map representing 
the percentage of genes that are shared between each pathway pair. B: Venn diagram of the overlapping 
pathways representing the transport of inorganic ions and amino acids process as well as the number of 
genes shared between them. C: Venn diagram of the overlapping pathways representing the post-
translational protein modification process as well as the number of genes shared between them. 
Figure 2. Functional-based network of each genetic pathway associated with psoriasis risk. A: 
“Inflammatory response”. B: “Natural killer T cell”. C: “Retinol metabolism”. D: “DNA repair”. E: 
“Transport of inorganic ions and amino acids”. F: “Post-translational protein modification”. The color of 
each gene represents the P-value of its association with psoriasis in the negative logarithmic scale, ranging 
from the lowest significance (green) to the strongest (red). The gene shape represents the association with 
the disease in neither the discovery nor the replication study (square), only in either the discovery or the 
replication study (circle) and the association found in both discovery and replication studies (rhombus). The 
edge width is proportional to the confidence of the functional association between two genes. Disconnected 
genes are hidden. 
Figure 3. N-Glycosylation on activated T lymphocytes according to MGAT5 genotype.  Boxplots of 
mean fluorescence intensity (MFI) of cell membrane glycosylation of in vitro activated CD4+ (left) and 
CD8+ (right) T cells from psoriasis patients. Patients with one and two copies of the protective (G) allele of 
MGAT5 SNP rs3791318, tend to have higher glycosylation levels, thus increasing the threshold for T cell 
receptor mediated response as well as lowering the threshold for cytotoxic T-lymphocyte-associated 
antigen-4 mediated arrest of T cell proliferation. 
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Supplemental Material 
The supplementary information is available in the online Supplemental Material file. 
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